Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign

Zivo Bioscience, Inc.

CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.
Company expects to file Form 15 on March 30, 2026 to suspend SEC reporting obligations and delist from OTC markets.
CEO letter states anticipated revenue from AgTech distribution partner in coming months, targeting first-time positive cash flow.
Board compensation eliminated; CEO continues to invest personal capital; alignment with shareholders emphasized.
University of Georgia granted funds to study Zivo's product for Avian Influenza using company's algal immune-modulating technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.